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Therapeutic senescence via GPCR activation in
synovial ﬁbroblasts facilitates resolution of arthritis
Trinidad Montero-Melendez 1,2*, Ai Nagano 3, Claude Chelala3,4, Andrew Filer 5,
Christopher D. Buckley 5,6 & Mauro Perretti 1,2*
Rheumatoid arthritis affects individuals commonly during the most productive years of
adulthood. Poor response rates and high costs associated with treatment mandate the search
for new therapies. Here we show that targeting a speciﬁc G-protein coupled receptor pro-
motes senescence in synovial ﬁbroblasts, enabling amelioration of joint inﬂammation. Fol-
lowing activation of the melanocortin type 1 receptor (MC1), synovial ﬁbroblasts acquire a
senescence phenotype characterized by arrested proliferation, metabolic re-programming
and marked gene alteration resembling the remodeling phase of wound healing, with
increased matrix metalloproteinase expression and reduced collagen production. This bio-
logical response is attained by selective agonism of MC1, not shared by non-selective ligands,
and dependent on downstream ERK1/2 phosphorylation. In vivo, activation of MC1 leads to
anti-arthritic effects associated with induction of senescence in the synovial tissue and
cartilage protection. Altogether, selective activation of MC1 is a viable strategy to induce
cellular senescence, affording a distinct way to control joint inﬂammation and arthritis.
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From Latin senēscere—to grow old—the process of cellularsenescence is a state of irreversible growth arrest whichserves as a potent tumor suppressor mechanism. Although
their ultimate fate is death, senescent cells remain highly meta-
bolically active for long periods and acquire a characteristic
phenotype, referred as the senescence-associated secretory phe-
notype (SASP) leading to context dependent outcomes1. Senes-
cence is a strategy favored by natural selection, evidencing its
positive protective value. However, senescence can also cause
tissue dysfunction typical with ageing, encouraging the develop-
ment of therapeutics based on senolysis or SASP reprogramming
as life-extension approaches2. The existence of these two faces of
senescence, one life-saving and another detrimental, is usually
explained by the antagonistic pleiotropy theory, suggesting that
ageing sits in the shadow of selection where harmful late-acting
processes can remain in a population as long as they confer
reproductive ﬁtness early in life, as later individual performance is
irrelevant for natural selection forces.
More recently, in addition to cancer and ageing, a prominent
role for senescence in tissue repair has emerged, particularly when
affecting ﬁbroblasts. Expression proﬁling analysis revealed that
senescent ﬁbroblasts get locked in an activated state that mimics
the early remodeling phase of wound healing3. Later, it has been
reported that senescent ﬁbroblasts accelerate would closure via
PDGF-AA secretion4 and facilitate the reversion of ﬁbrosis in a
mouse model of liver cirrhosis5. In the human synovium, ﬁbro-
blasts are key effectors of tissue destruction in rheumatoid
arthritis (RA). Fibroblast main role is to provide structural sup-
port, lubrication to allow low friction movements of the articular
joints and nutrients to the avascular cartilage. This benign sce-
nario changes dramatically during RA6,7. The synovial layer
transforms into a hyperplastic invasive tissue, expanding up to
10–20 cells thick in which synovial ﬁbroblasts (SFs) acquire an
aggressive proliferative phenotype turning into cytokines fac-
tories, driving cartilage and bone destruction, and promoting
sustained recruitment and retention of immune cells. Thus, SFs
do not merely respond to inﬂammatory stimuli, but become
active aggressors in the RA joints.
The aggressive behavior of SFs in RA can be a consequence of
failure of resolution of inﬂammation. While the resolution of
inﬂammation may be perceived as a separate entity from the pro-
inﬂammatory phase, pro-resolving mechanisms and mediators
are activated in parallel to pro-inﬂammatory mechanisms8,9. SFs
from RA patients retain their aggressive phenotype in the absence
of any inﬂammatory stimulus7. Although SF activation lies
downstream of the hierarchy of events that trigger RA, these
involving predominantly immune cell inﬁltration, their failure to
switch off after stimulation contributes to the destructive chronic
inﬂammation typical of the RA joint6. Targeting SF may repre-
sent a promising strategy for reverting chronicity and inducing
long-term remission, without inducing immunosuppression.
Melanocortin (MC) receptor agonists are promising candidates
for the treatment of inﬂammatory conditions, including colitis10,
myocardial and cerebral ischemia11,12, Alzheimer13, multiple
sclerosis14, and RA15. The MC agonist adrenocorticotropin hor-
mone (ACTH) is effective in human RA as shown over 60 years
ago16. There is more recent evidence that MC therapy leads to
protective actions including reduced ﬁbroblast activation, osteo-
blast proliferation, and improved chondrocyte function17–19. In
vivo, the synthetic peptide D-Trp8-γMSH reduces clinical signs of
disease in experimental inﬂammatory arthritis20 and urate crystal
peritonitis21. In addition, the pan-MC agonist AP214 and the
biased AP1189 small molecule also display anti-arthritic
properties15,22. In the present study, we aimed to investigate the
potential therapeutic properties of MC drugs on SF from RA
patients. Interestingly, we observe that selective activation of the
melanocortin receptor MC1 on SF promotes cellular senescence.
This receptor, with a non-redundant role in skin pigmentation,
is endowed with anti-inﬂammatory actions23. MC1-mediated
senescence leads to remarkable therapeutic consequences: cessa-
tion of SF proliferation and acquisition of a pro-repair phenotype
that highly resembles that observed during senescence-driven
wound healing3–5. This effect is achieved by activation of the
receptor by a small-molecule agonist, and it is the ﬁrst reported
evidence of cellular senescence induced through direct activation
of a G-protein coupled receptor (GPCR).
Results
The MC system is functional in SFs. We examined expression
and functionality of the MC system in human primary joint SF
(Supplementary Table 1). Receptors (MC1R, MC2R, MC3R,
MC4R, MC5R), ligands, and precursors (POMC, ASIP, AGRP),
processing enzymes (PCSK1, PCSK2), and accessory proteins
(MRAP1, MRAP2) were studied. MC1R, MC3R, MC4R, and
MC5R receptors were detected at the mRNA level, together with
other members of the MC pathway (Fig. 1a). MC1R displayed the
highest expression among the four receptors (Fig. 1b). SF could
release the endogenous anti-inﬂammatory peptide ACTH
(Fig. 1c). With respect to receptor activation, the natural pan-
agonist αMSH and the MC1-selective compound BMS-470539
(BMS)24 induced ERK-phosphorylation (Fig. 1d), although they
did not elevate cAMP, the canonical pathway described for this
family of GPCRs25 (Fig. 1e). Both αMSH and BMS raised intra-
cellular Ca2+ (Fig. 1f). Functionally, MC receptor activation did
not result in remarkable differences on early cellular responses
(24–48 h) including scratch gap closure, cytokine release, SF
migration or invasion (Fig. 1g–i), though some of the modest
effects reached statistical signiﬁcance.
Selective MC1 activation induces senescence via ERK1/2. Both
αMSH and BMS reduced 7-day cell proliferation (Fig. 2a).
However, cells treated with BMS exhibited a number of speciﬁc
features including expansion of the lysosomal compartment,
presence of bi-nucleated cells, increase in cellular activity—Ala-
mar blue assay—and increases in the extent of β-galactosidase-
positive staining (Supplementary Fig. 1A–D). All these outcomes
suggested induction of cellular senescence, a feature that was
conﬁrmed in a concentration–response assay (Fig. 2b). Interest-
ingly, the pan-agonist αMSH, even when tested for prolonged
periods up to 2 weeks, did not produce any of these changes;
similar inefﬁcacy was observed with the dual MC1/MC3 agonist,
[D-Trp8]-γMSH (Supplementary Fig. 1D). The tumor suppressor
protein p53 was up-regulated by BMS treatment (Fig. 2c), toge-
ther with the senescence marker p16INK4, whose expression
correlated with senescence-associated β-galactosidase (SA-βGal)
(Fig. 2d). MC1 selective activation also induced p16INK4 expres-
sion in SF grown as 3D organoids (Fig. 2e).
To establish speciﬁcity, experiments were conducted in other
cell types. Indeed, these pro-senescence effects downstream
selective MC1 activation were not replicated with human primary
macrophages (Fig. 2f) or murine melanocytes (Fig. 2g). On the
latter cell type, BMS was a potent inducer of melanin synthesis
(Supplementary Fig. 1E, F); as predicted this effect was not
observed in SF, denoted by lack of melanin production and
tyrosinase gene expression (Supplementary Fig. 1G, H). Interest-
ingly, BMS also induced senescence in human dermal ﬁbroblasts
(Supplementary Fig. 1I), indicating that (i) this distinct mechan-
ism may be of broader biological signiﬁcance and (ii) this
observation may be of translational value for skin conditions
characterized by aberrant ﬁbroblast proliferation and activation.
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The selectivity of BMS was conﬁrmed in HEK293 cells
transfected with MC1 (Supplementary Fig. 1J), a cell type selected
because lacking MC receptors, hence devoid of this confounding
element. BMS yielded a clear concentration–response curve in
MC1-HEK293 (calculated EC50= 2.8 nM) monitoring cAMP
accumulation. However, MC receptor can signal through multiple
pathways23. BMS activated ERK-phosphorylation in MC1-trans-
fected HEK293 cells and displayed a partial agonistic activity at
MC3-transfected HEK293 (Supplementary Fig. 1J). Given that SF
expressed all MCRs, with the exception of MC2R, the effective
contribution of MC1 was further investigated. Primary SF from
mice deﬁcient in either Mc1r or Mc3r were tested for BMS pro-
senescence activity. Such activity was abrogated by absence of
functional MC1 yet fully preserved in Mc3r−/− joint ﬁbroblasts
(Fig. 2h). The pro-senescence effect of BMS in murine SFs was
prevented by the ERK inhibitor FR180204. Co-incubation of BMS
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Fig. 1 The Melanocortin (MC) system in synovial ﬁbroblasts. a Expression of several components of the MC pathway in RA SF ﬁbroblasts as determined
by end-point PCR using 1 μg of RNA (n= 4). b MCRs expression was further analyzed by real-time PCR using 1 μg of RNA. Cycle threshold (CT) values
normalized against the reference control HPRT1 are shown (lower CT values denote higher expression). Numbers above bars indicate overexpression of
MC1R compared to the other receptors calculated as 2−ΔΔCt. Data represent mean values, min to max range (n= 12, one-way ANOVA, Dunn’s correction;
**p < 0.01; ***p= 0.001). c ACTH quantiﬁcation in supernatants on SF cultured for 7 days without media replacement. Data are mean ± SD (n= 15). Dotted
line represents values quantiﬁed in media without incubation with SF cells, serving as a negative control. d ERK-phosphorylation as analyzed by western
blotting after 5 min stimulation of SF with MC agonists at the indicated concentrations. e Intracellular cAMP accumulation was quantiﬁed by EIA after
15 min SF cell stimulation with BMS or αMSH. The adenylyl cyclase activator forskolin (3 μM) was used as a positive control, yielding 0.58 pmol/ml. Data
are mean ± SE (n= 3). f Ca2+ mobilization in SF upon addition of αMSH or BMS (from 1 μM then serially diluted up to 10 pM), and recorded for 86 s.
Ionomycin (1 μM) was used as a positive control, yielding 0.15 units of absorbance ratio at 340/380 nm. Data are mean ± SE (n= 3). g In vitro wound
healing assay conducted using ibidi® chambers on SF cells stimulated with 10 μM αMSH and 1 μM BMS. Representative images show gap closure. Scale
bars indicate 100 μm. Data are mean ± SE (n= 6, two-way ANOVA). h Cytokines release from SF stimulated with SAA at 10 μg/ml and treated with αMSH
(30 μM) or BMS (10 μM) for 24 h, determined by ELISA. Data are mean ± SE (n= 15, one-way ANOVA vs. control; *p < 0.05). i Transwell® inserts were
used for SF migration (Mig) and invasion assays on Matrigel®-coated wells (Inv). Cells were treated overnight with 10 μM BMS. Data are mean ± SE (n= 6,
Student’s t-test vs. control). Source data are provided as Source Data ﬁle.
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with the MC1 natural antagonist ASIP resulted in decreased
SF senescence, an inhibition not afforded by the MC3/MC4
antagonist AGRP (Fig. 2i).
Since GPCRs commonly bind multiple ligands, we applied a
β-arrestin screening to monitor potential off-target effects of BMS.
Out of 168 different GPCRs tested (Fig. 2j), BMS activated MC1 as
a full agonist while displayed partial activity at other MCRs; a very
weak activity (~30%) was detected for the ghrelin receptor (GHS
receptor). However, RT-PCR analysis revealed that SF do not
express GHSR (Fig. 2k). This dataset allows us to conclude that
BMS is highly selective for MC1 and its activity is not secondary to
the engagement of other known GPCRs. Collectively, these data
indicate that MC1-selective activation induces cellular senescence
in primary SF via phosphorylation of ERK.
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Fig. 2 Cellular senescence induced by selective MC1 agonism. a SF cells were treated for 7 days with 10 μM αMSH or 1 μM BMS and proliferation
assessed by cell counting. Data are mean ± SE (n= 13, Student’s t-test vs. control; **p < 0.01, ***p < 0.001). b Cells were treated with BMS or αMSH for
7 days and SA-βGal+ cells quantiﬁed. Scale bars indicate 100 μm. Data are mean ± SE (n= 2, two-way ANOVA; **p < 0.01). c p53 protein levels were
analyzed by western blot after 7-day treatment of SF cells with 3 or 10 μM BMS (B) or 10 μM αMSH and bands quantiﬁed (fold change with respect to
vehicle). Data are mean ± SE (n= 6, Student’s t-test vs. control, C; *p < 0.05). d Immunoﬂuorescence for p16INK4 in SF cells treated with 1 μM BMS was
performed on SA-βGal-stained cells to determine their association. Scale bars indicate 200 μm. e SF cells were grown on Matrigel®-based 3D spheroids for
3 weeks with or without 1 μM BMS. p16INK4 was determined by immunoﬂuorescence. Scale bars indicate 200 μm. f Effect of BMS on SA-βGal and p16INK4
staining in human macrophages incubated with 1 µM BMS for 7 days. Data are mean ± SE (n= 5, Student’s t-test vs. control, Ctrl). g Senescence on B16-F10
mouse melanocytes (1 µM BMS for 7 days) was determined by SA-βGal staining. Scale bars indicate 1000 μm. h SF were isolated from the joints of wild
type (WT), Mc1re/e, or Mc3r−/− mice and treated with 1 μM BMS (B) and/or the ERK1/2 inhibitor FR180204 (ERK−; 1 µM) for 7 days. Senescence was
quantiﬁed by SA-βGal staining. Data are mean ± SE (n= 4–6, Student’s t-test vs. control, C). i Senescence was induced in SF with 1 μM BMS and
determined by SA-βGal staining. The MC1 antagonist ASIP or MC3/MC4 antagonist AGRP were used at 50 nM. Data are mean ± SE (n= 3, Student’s t-test
vs. control, C; **p < 0.01, ***p < 0.001). j BMS (10 µM) was tested on the PathHunter β-Arrestin assay. Data represent % activation respect to positive
controls: αMSH for melanocortin receptors and ghrelin for GHS receptor. k RT-PCR for the reference control HPRT1, and the ghrelin receptor GHSR on three
different SF cells lines with expected bands at 130 and 148 bp, respectively. Source data are provided as Source Data ﬁle.
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MC1-mediated senescence leads to a tissue repair proﬁle.
Senescence is often associated with a speciﬁc secretory phenotype
called SASP, which typically includes cytokines. However, the SASP
induced by BMS on RA SF did not exhibit this pro-inﬂammatory
phenotype, as levels of CCL-2, IL-6, or IL-8 were reduced (Sup-
plementary Fig. 1K). To fully elucidate the phenotype acquired by
BMS-induced senescence in SF, we conducted RNA sequencing
analysis. SF were treated with BMS (using the 7-day incubation
protocol) and subjected to whole-genome RNA sequencing. This
analysis identiﬁed statistically signiﬁcant (p < 0.05) changes in 1952
genes, of which 19 were selected for validation by qPCR (Fig. 3a, b,
Supplementary Tables 2 and 3), indicating a robust correlation
between RNAseq and qPCR data. Modulation of several genes
related to senescence and cell cycle regulation was identiﬁed
(Fig. 3c, Supplementary Fig. 2A), including down-regulation of
cyclins (CCND2, CCNI), up-regulation of the CDK inhibitors
p16INK4, p21, and p15 (CDKN2A, CDKN1A, CDKN2B), and
increase of pro-survival signals typical of senescent cells (BAG1,
9231029
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BCL2). A basic analysis of bio-functions (Panther Classiﬁcation
System) was performed, revealing a prominent role for metabolic
processes and enzymatic activity in the genes regulated by BMS
(Fig. 3d). A protein–protein interaction (PPI) network was con-
structed with all 1952 differentially regulated genes and coupled
with functional clustering using DAVID v6.8 (Fig. 3e), revealing a
number of highly interacting processes altered by SF treatment
with BMS. These included cell cycle regulation, metabolic processes,
lysosomal components, and immune system responses. The
expression of multiple extracellular matrix-related genes was dys-
regulated, consistent with the senescence-associated pro-repair
proﬁle as reported in different contexts3–5. A closer examination
of these genes revealed a pro-remodeling phenotype (Fig. 3f),
characterized by marked down-regulation of collagens (COL1A1,
COL3A1, COL5A1) accompanied by increase in metalloproteases
(MMP3, MMP11), and down-regulation of enzymes involved in
matrix degradation (ADAMTS1, ADAMTS2). Additional genes
relevant to the senescent phenotype involved in cell cycle regulation
and lysosomal function were observed (Fig. 3f). The ﬁndings cor-
roborate the senescence status of BMS-treated SF and the potential
beneﬁt that it may ensue for tissue repair. We also found down-
regulation in multiple genes linked to SF aggressive phenotype,
either involved in immune cell recruitment (CCL2), T-cell retention
(CXCL16), angiogenesis (VEGFA), bone destruction (MSTN), or
cellular activation (CD74, IL18R1) (Fig. 3g, Supplementary Fig. 2B).
Out of this wealth of data we decided to focus on the relationship
between senescence and tissue repair.
Query of the databases CellAge and TiRe retrieved 37 and 38
genes altered by BMS related to senescence and tissue repair,
respectively. The PPI network of these genes (Fig. 3h) suggests
they are highly interrelated processes. A Connectivity Map
analysis revealed that BMS-induced transcriptional proﬁle in SF is
highly similar to drugs known to negatively impact on the cell
cycle (Fig. 3i). Extended information on all genes reported in
Fig. 3 is presented in Supplementary Table 3.
Inactivation of Notch mediates BMS-induced senescence. To
gain more insight into the mechanism of BMS-induced senescence
in SF, a pathway enrichment analysis was conducted using the
whole dataset of differentially expressed 1952 genes. In line with
the outcomes above, extracellular matrix and lysosome related
pathways were highly enriched in BMS-treated SF (Fig. 4a),
together with a strong modulation of lipid metabolism. The Notch
signaling pathway emerged too, a pathway that plays a crucial role
during embryonic development and cancer26. All genes related to
Notch signaling were down-regulated by BMS treatment, includ-
ing the ligands JAG1 and NOTCH3 (Fig. 4b, Supplementary
Table 3). We conﬁrmed the down-regulation of Notch3 protein in
SF, with reduced levels of the protein evident from day 5 after
BMS treatment (Fig. 4c, d). To test the causal engagement of this
pathway in BMS-induced senescence, SF were treated with BMS,
in presence or absence of the delta like canonical Notch ligand 4,
DLL4, and senescence quantiﬁed by p16INK4 staining. BMS sig-
niﬁcantly augmented p16INK4+ cells, but this effect was overrun
by co-administration of DLL4 (Fig. 4e), indicating that inhibition
of the Notch pathway is at least one of the functional mechanisms
behind the pro-senescence property of BMS.
Metabolic reprogramming contributes to MC1- senescence.
Two of the analysis presented above indicated that changes in
lipid metabolism are a prominent feature of MC1-mediated
senescence. Functional analysis of senescence-related genes
(retrieved from CellAge database) revealed that metabolism is
altered during senescence (Fig. 5a). Further dwelling into BMS-
altered genes unveiled a marked up-regulation of the cholesterol
synthesis pathway, with essentially all enzymes from acetyl-CoA
till conversion into bile acids being up-regulated (Fig. 5b), with
shunting off cortisol synthesis with down-regulation of CYP11A1.
A PPI network built with CellAge genes and the cholesterol
pathway genes revealed that these two processes are highly
interactive (Fig. 5c). This genomic response was conﬁrmed by
elevated levels of cholesterol and extracellular bile acids upon
treatment of SF with BMS (Fig. 5d).
To address whether there was a functional link between this
metabolic cascade and senescence, SF were treated with BMS with
or without atorvastatin to block the biosynthesis of cholesterol, by
inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR). Atorvastatin attenuated BMS induced SF senescence
by ~40% (Fig. 5e). Similarly, the increase in secreted bile acids in
supernatants suggested a possible role of these lipids in the
secretome characteristic of BMS-induced senescent cells. As
macrophages, present in the synovial lining, express the bile acid
receptor GPBAR1 (Fig. 5f), the effect of bile acids secreted by SF
on macrophage viability was determined. Human primary
monocyte-differentiated macrophages were incubated with super-
natants from senescent SF and the GPBAR1 antagonist 5β-
cholanic acid. Incubation of macrophages in the presence of
senescent supernatants yielded a modest increase in apoptosis
(Fig. 5g) that was prevented by the antagonist. The impact on
macrophage apoptosis by 5β-cholanic acid was conﬁrmed
through cleaved caspase-3 immunoﬂuorescence. Supernatants
from non-senescent cells or direct exposure of macrophages to
BMS did not produce any signiﬁcant modulation of apoptosis
(Fig. 5g, h).
Senescence contributes to BMS pro-repair actions in vivo. To
ascertain whether senescence contributed to the anti-arthritic
Fig. 3 Gene expression proﬁle acquired during MC1-mediated cellular senescence. a RNAseq analysis on SF (n= 8 patient cell lines) treated with 1 μM
BMS, identiﬁed 1952 statistically signiﬁcant (p < 0.05) differentially expressed genes which are presented as a volcano plot: fold change from BMS vs.
control, against p value. Highlighted genes were validated by real-time PCR. b Nineteen genes (details in Supplementary Table 3) were selected for
expression validation using SYBR Green real-time PCR and fold changes calculated as 2−ΔΔCt. Values obtained by both techniques are presented against
each other. Data are mean ± SE (n= 8 SF cell, Pearson’s correlation). c Senescence-related genes signiﬁcantly altered by BMS treatment and their
differential expression value: up-regulated in red, down-regulated in green. d Functional proﬁling of all 1952 differentially expressed genes identiﬁed by
RNAseq using Panther Classiﬁcation System. e Protein–protein interaction (PPI) network built with all 1952 signiﬁcantly altered genes using STRING.
Further functional analysis was performed with DAVID and signiﬁcantly enriched categories are highlighted. f Selected genes associated with biological
functions of interest are shown with their respective expression values (up-regulated in red, down-regulated in green) together with a correlation matrix
constructed with all genes in each category. g PPI network constructed with selected genes related to SF activation and aggressive phenotype. The fold
changes of down-regulated genes (in green) induced by BMS are shown. h Genes related to senescence and tissue repair were retrieved from CellAge and
TiRe databases, respectively, and a merged PPI network generated using STRING. i Connectivity map analysis shows positive association (i.e. positive
score, maximum score can be 100) between the BMS-induced genes identiﬁed through our RNAseq analysis and the gene expression proﬁles induced by
drugs included in the Connectivity Map database. Source data are provided as Source Data ﬁle.
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effect of BMS, we used a model of inﬂammatory arthritis,
administering BMS (18 mg/kg i.p. per day) after arthritis onset
(day 3) and observing inhibitory actions on clinical score and paw
swelling (Fig. 6a). Positive staining for the senescence marker
p16INK4 was detected in the joint synovial lining exclusively in
BMS-treated mice (Fig. 6b; validation of the p16INK4 antibody is
provided in Supplementary Fig. 4). To determine to what extent
the anti-arthritic actions of BMS depended on the pro-senescence
effect, we determined the effect of senolytic drugs, quercetin and
dasatinib27.
Indeed, a co-therapy protocol with senolytic drugs prevented
the anti-arthritic effect of BMS with a clearer outcome on the
clinical score, and less clear on the modulation of paw edema
(Fig. 6c). Immunoﬂuorescence analysis of knee sections revealed
efﬁcient removal of p16INK4-positive cells in the animals co-
treated with the senolytics (Fig. 6d). Co-staining with p16INK4
and the SF marker cadherin-11 demonstrates co-localization
and induction of senescence selectively in SF cells (Fig. 6e). Knee
and ankle joints were analyzed to measure the degree of
cell inﬁltration and cartilage integrity (Fig. 6f, g), yielding a
cumulative damage score calculated as shown in Supplementary
Fig. 3. BMS reduced this damage score by ~35%, a protection
prevented by co-administration of senolytics (Fig. 6f, g). Finally,
treatment of mice with BMS promoted cellular senescence
exclusively in SF, with no detectable induction of p16INK4
observed in any of the seven other tissues tested (Supplementary
Fig. 5).
Association of MC1R genetic variants with SF response to
BMS. MC1R is a highly polymorphic gene with a high frequency
of variants associated with loss-of-function, accounting for skin
and hair color variation in the human population. MC1R variants
reported in the GPCR Natural Variants Database (a total of 83)
were analyzed in SF from 20 patients. Eight different variants
were detected, with allele frequencies (q) ranging from 2.5% (e.g.
V60L) to 10% (V92M, D294H) (Fig. 7a). No homozygotes were
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found for any of the variants. However, 55% of patients carried at
least one variant, suggesting the importance of discerning their
impact on MC1-based therapies (Fig. 7a). Notably, 25% of
patients presented with 2 different variants, yielding a total of 10
different haplotypes (Fig. 7b). A proliferation assay and senes-
cence induction (1 μM BMS, 7 days) on cells from these 20
patients was conducted. Strikingly, all patients who did not
respond to BMS (4 out of 20, hence 20%) carried the variant
D294H, one of the loss-of-function SNPs more strongly asso-
ciated with red hair28 (Fig. 7c). Presence of this variant was not
observed in the responders cells. Consistently, a robust senes-
cence response was induced in the responders, while this effect
was markedly attenuated in cells classiﬁed as non-responders and
bearing the D294H variant (p= 0.0002, two-tailed Fisher’s test).
The fact that we did not observe abrogation of the effect is likely
due to the heterozygous status and hence the presence of a wild
type allele that might drive part of the effect. In line with the
molecular and cellular mechanisms presented above, production
of cholesterol was also markedly reduced in SF on the non-
responders group. SA-βGal staining of the SF cells paralleled
these results (Fig. 7c).
This genomic analysis reveals a potential therapeutic impact of
variants of the MC1R gene like D294H. Other common variants
weakly associated with the red hair phenotype do not seem to
impact the cellular response evoked by BMS in SF.
Discussion
We report evidence of therapeutic induction of cellular senes-
cence in inﬂammatory arthritis through selective activation of a
GPCR, providing the dual beneﬁt of arresting proliferation of
hyper-proliferative aggressive ﬁbroblasts together with the
induction of a pro-reparative phenotype. Previous pro-senescence
approaches, mainly developed as anti-cancer therapies29, have
been based on the use of ionizing radiation, intercalating agents
causing DNA damage or small molecules to directly interfere with
cell cycle components. GPCRs30 are highly druggable targets,
representing ~30% of marketed small-molecule drugs31. The
discovery of this pro-senescence action via activation of MC1
could represent a promising therapeutic avenue for arthritis and
possibly other ﬁbroblast-related conditions.
The molecular mechanisms leading to senescence are com-
plex and affected by speciﬁc microenvironment and cellular
context1,29. Senescence can be induced by replication exhaustion
when a cell reaches the Hayﬂick limit and telomere attrition is
sensed as an irreparable DNA damage. A second type of cellular
senescence serves as a major tumor suppressor mechanism and
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results from oncogenic stress due to activating mutations in
oncogenes (e.g. BRAF) or inactivating mutations in tumor
suppressor genes (e.g. PTEN). Senescence can also occur by less
understood mechanisms including oxidative stress, mitotic
stress or the unfolded protein response2. The type of senescence
we report here induced by selective MC1 activation is difﬁcult to
categorize into previously described classes of senescence. Fol-
lowing BMS treatment, SF displayed several hallmarks of
senescence, including proliferation arrest, lysosomal expansion,
SA-βGal and p16INK4 staining, down-regulation in cell cycle
promoters, and up-regulation in anti-apoptotic signals. It is
unlikely that BMS induced replicative or oncogene-related
senescence, due to absence of abnormalities like DNA-SCARS,
i.e. nuclear foci indicative of DNA damage. The senescence
process presented in this study might rely on mechanisms dif-
ferent from those previously described since they are initiated by
membrane receptor signaling activation. Congruently, the SASP
induced by BMS on RA SF cells did not resemble the typical
pro-inﬂammatory proﬁle of SASP, as levels of CCL-2, IL-6, and
IL-8 were modestly down-regulated rather than up-regulated.
There is evidence, however, that the nature of the SASP is
context dependent and it is not always associated with a pro-
inﬂammatory proﬁle32,33, a notion consistent with the existence
of distinct senescence phenotypes discussed above.
Encouraged by the anti-inﬂammatory properties of MC ago-
nists23, we initiated this study to elucidate the biology of MC
receptors on SF activation, observing ﬁrstly that multiple com-
ponents of the MC system were expressed in SF. In receptor
activation assays, SF showed a biased activation proﬁle compared
to other cell types, given that neither the natural αMSH nor the
synthetic BMS (as well as ACTH and [D-Trp8]-γMSH, data not
shown) promoted accumulation of cAMP, the canonical MC-
signaling pathway15 but their application yielded phosphorylation
of ERK1/2. Although unexpected, these results are consistent with
a study34 reporting that αMSH does not increase, but rather
decreases, cAMP levels in H-211 ﬁbroblast cells. Elevation of
cAMP has been reported in other types of ﬁbroblasts35, sug-
gesting context-dependent outcomes and potential technical dif-
ferences. The acute (24 h treatment) anti-inﬂammatory properties
of all MC receptor agonists tested in SF were modest, with partial
reduction of secreted CCL-2, CXCL-5, and IL-6 levels. However,
prolonged treatment (7 days) induced cellular senescence. Of
note, MC activation has not previously been related to senescence
and Mc1re/e mice do not display any susceptibility to cancer
(other than UVR-induced), ageing, or altered lifespan. In addi-
tion, the fact that endogenous αMSH does not induce senescence
may explain why this effect has not been observed previously.
Therefore, MC1-induced senescence is not an effect that could be
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envisaged from the physiological actions. We postulate that
selective activation of MC1 holds the clue to induction of senes-
cence, leading to a functional outcome distinct to that produced
by simultaneous activation of multiple receptors (attained with
αMSH). This mechanism may also involve the differential for-
mation of homo- or hetero-dimers by αMSH and BMS, leading to
distinct functional outcomes. As BMS-470539 is the only MC1
selective small molecule ever reported, full elucidation of this
intriguing mechanism of action will require the joint effort of
chemists and computational biologists towards the development
of new compounds.
An omics approach was used to characterize the phenotype
acquired by BMS-treated SF. Gene expression proﬁles observed in
BMS-treated cells corroborated the senescent phenotype, with
identiﬁcation of several genes involved in cell cycle arrest, pro-
survival signals, and up-regulation of lysosomal components, all
features of senescence. Additional functional clusters were sug-
gestive of ﬁbroblast de-activation and promotion of tissue repair.
The most prominent change includes down-regulation of col-
lagens mirrored by an increase in MMPs expression. A marked
down-regulation of ADAMTS enzymes was also observed. These
enzymes are involved in the degradation of aggrecan leading to
cartilage damage: down-regulation by BMS may underlie further
protective actions on the RA joint.
This gene analysis revealed important clues on the molecular
mechanism underpinning BMS-mediated SF senescence. Several
elements of the Notch pathway were markedly down-regulated
and further experimental validation suggested that this down-
regulation was not consequence but rather a contributor to
the senescence program activated by BMS. Notch signaling plays
a crucial role during embryonic development and cancer26, and
its inhibition has been proposed as a potential anti-cancer
therapy36,37 In our hands, activation of the pathway using a
recombinant ligand abrogated the pro-senescence effect of BMS.
This ﬁnding can be highly relevant since the Notch pathway may
play a role in the pathogenesis of RA. Activation of Notch is
typical of RA synoviocytes and it mediates their proliferation in
response to TNFα38; thus, inhibition of Notch signaling has been
proposed as a viable approach to target RA39. Selective MC1
activation may be dually beneﬁcial in RA, via the inhibition of
Notch and subsequent induction of senescence.
RNA sequencing analysis revealed a strong adaptation of
metabolic programs, in particular the cholesterol pathway, with
all its components (biosynthetic enzymes and regulatory pro-
teins) being up-regulated. Cells may require an increase in the
production of cholesterol for different purposes. One may be
production of steroid hormones, a pathway we excluded since
enzymes responsible for the conversion of cholesterol into cor-
tisol, such as CYP17A1, CYP11B1, or HSD3B1, were not found
expressed in SF (RNAseq). Neither the enzymes leading to pro-
tein prenylation using precursors produced from the HMG-CoA-
reductase pathway were modiﬁed by BMS. Cholesterol is needed
to provide structural integrity and ﬂuidity to cell membranes.
Its increased production in BMS-treated SF might reﬂect an
expansion of lysosomal compartment, consistent with the up-
regulation of NPC1 and NPC2 involved in cholesterol trafﬁcking
to lysosomes. Interactome analysis of the cholesterol pathway
and senescence-related genes revealed that these two processes
are highly interconnected. Congruently, inhibition of HMG-CoA
reductase with atorvastatin signiﬁcantly impacted on the induc-
tion of senescence by BMS. The metabolic reprogramming
evoked by selective MC1 activation ended to bile acid production,
suggesting that augmented cholesterol might impact on cell
behavior beyond lysosomal expansion.
Since SF and macrophages are the major cell types present
within the synovial lining, we evaluated if SF-derived bile acids
could might have any effect on macrophages, which express the
bile acid receptor GPBAR140. We observed that bile acids released
by SF had mild effects on macrophage apoptosis, an action that
was abrogated by application of a GPBAR1 antagonist. These data
suggest that BMS-induced metabolic rewiring of SF induces
senescence and impact on the type of secretome released by
senescence cells. While further studies are needed to fully eluci-
date the role of lipid metabolism and their regulation of neigh-
boring synovial macrophages, herein we prioritized our efforts on
addressing the potential therapeutic value of SF senescence and
the associated tissue repair program in the context of joint
inﬂammation. We made use a mouse model of inﬂammatory
arthritis41 susceptible to MC agonists15,22,42.
In arthritic mice, BMS induced p16INK4 expression within the
synovial lining of arthritic joints, indicating genuine induction of
senescence in vivo, while at the same time, reducing clinical score
and joint swelling. However, MC1 receptor activation may lead to
further anti-inﬂammatory effects via reduction of leukocyte inﬁl-
tration and cytokine release24,43,44. Thus, we deemed important to
evaluate the contribution of SF senescence on the anti-arthritic
properties of BMS and we used senolytic drugs. Senolysis consists
of the selective killing of senescent cells by targeting their sore
point, that is, the pro-survival pathways that make them resistant
to the hostile environment induced by their own SASP2,27.
Arthritic mice treated with a seno-cocktail consisting of quercetin
and dasatinib (effective in eliminating senescent cells in vivo27)
revealed elimination of synovial lining senescent cells induced by
BMS. This outcome at the cellular and tissue level was paralleled
by prevention of the tissue protective actions of BMS on joint
inﬂammation and cartilage integrity while the seno-cocktail was
less effective on paw swelling (an action plausibly linked to MC1
modulation of prostanoid and cytokine production).
The process of senescence might not be intrinsically detri-
mental, yet inefﬁcient removal of senescent cells from tissues due
to immune system deterioration associated with ageing, may yield
a negative outcome45. Long-term studies will be required to
determine if, in the context of joint inﬂammation, the immune
system is capable of eliminating the senescent cells induced by
BMS, or if a senolytic approach after a pro-senescence therapy
might be required to optimize therapeutic outcome. Interestingly,
a senolytic rather than a pro-senescence approach has been tested
in experimental osteoarthritis (OA)46. The authors used the ele-
gant trimodality-reporter mouse model p16-3MR, engineered to
direct expression of pro-apoptotic proteins under the promoter of
p16INK4 gene, inducing apoptosis selectively on senescent cells4,
to reveal protection on cartilage integrity by the elimination of
senescent cells. As known, there are fundamental differences
between RA and OA including their relation with ageing. For OA,
age is one of the most important risk factors. Senescence in
chondrocytes may play an important role in OA pathogenesis by
affecting cartilage integrity, similarly to other senescence-related
diseases like pulmonary ﬁbrosis in which senescence also occurs in
parenchymal cells (alveolar epithelial cells). Another crucial aspect
underlying the dual beneﬁcial or detrimental outcome of senes-
cence is the inefﬁcient clearance of senescent cells due to impaired
immune surveillance what is responsible for the damaging effects
of the SASP45. In RA, however, the existence of aggressive SF in a
proliferation mode might encourage a pro-senescence therapy. It
is almost two decades since p16INK4 activation in joints was
suggested as a viable anti-arthritic therapy47. However, the con-
cept of cellular senescence was not deeply considered at the time,
nor was the powerful value of senescence on tissue repair. In
addition, the difﬁculties derived from adenoviral-based transfer of
p16INK4 into the joints proposed at the time might have dis-
couraged that approach. Here we identiﬁed a small molecule,
orally bioavailable, able to induce senescence downstream GPCR
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activation and without the need for gene therapy. It remains to be
seen what could be the consequences, and possible side effects,
associated with long-term treatment with this approach prior to
further therapeutic developments.
MC1R is a highly polymorphic gene, and more than 200 var-
iants have been described48. This variation is associated with the
diversity in human normal pigmentation. MC1R variants are
found in around 80% red/blonde hair poor tanning individuals
and are strongly associated with skin cancer risk28. Diminished
MC1 function leads to impaired melanin production, which
increases skin vulnerability to UV radiation and compromises
nuclear excision repair mechanisms. Distinct mechanisms can
lead to MC1 loss of function, including uncoupling from the G-
protein, limited surface expression, or alterations in the agonist
binding sites49. Consequently, the high frequency of these var-
iants in the population may impact on the development of MC1-
based therapies.
RA management is suffering from a high economical burden
derived from the poor response rates to current treatments (~40%
failure)50,51. The inability to predict treatment responses trans-
forms RA management into trial-and-error algorithms. Precision
medicine approaches should be incorporated into the drug
development process to maximize treatments beneﬁts: as such
MC1 is an ideal drug target in which this approach might be
feasible as multiple variants and their functional outcomes are
known. A high proportion (55%) of patient cells studied here
carried at least one variant, and consistent with previous studies
on similar populations (British/Irish), multiple highly penetrant
variants (R alleles) with strong association with red hair were
identiﬁed28. In general, MC1R variants did not associate with the
effects of BMS on SF senescence: however, the R variant D294H
was associated with reduced BMS-induced senescence. Although
other R alleles were also identiﬁed (R151C, R160W, D84E),
D294H variant considerably differs in the mechanism leading to
loss of function, as it increases cell surface expression (in contrast
to the other variants) possibly due to its resistance to inter-
nalization derived from defective G-protein coupling and hence
deﬁcient signaling52. Larger studies will be necessary to provide a
conclusive association of D294H, and maybe other variants, with
a reduced MC1-mediated pro-senescence effect. The high number
of possible variants and their multiple combinations as com-
pound heterozygous, together with the absence of homozygous in
this study limits the possibility of creating a rule to predict
response. However, these initial ﬁndings suggest a likely role for
the D294H variant, present in >50% of red hair individuals28, on
the efﬁcacy of BMS to induce SF senescence, and more generally
emphasizes the importance of incorporating pharmacogenomics
analysis on MC1-based therapies, to ensure that the right drug is
given to the right patient.
In summary, selective activation of the GPCR MC1 may help
restoring the broken homeostasis in the RA synovium, preventing
the vicious cycle of reciprocal activation between SF and mac-
rophages and other cells within the inﬂamed joint environment.
The molecular signature of SF upon MC1-mediated senescence
induction is consistent with a pro-reparative proﬁle. We are
gradually deciphering cells and mechanisms that determine
resolution and appreciate persistent inﬂammation may derive not
only from exacerbated pro-inﬂammatory signals but also from
defective engagement of resolution programs. These data suggest
that a therapeutic opportunity may arise from the exploitation of
senescence to target SFs that in RA fail to switch off.
Methods
Human primary SFs. Patients with RA involved in this study were diagnosed
according to the 1987 American College of Rheumatology (ACR) criteria. This
study complied with all relevant ethical regulations. The study was approved by the
National Research Ethics Service (NRES) Committee West Midlands—The Black
Country Ref. 07/H1204/191, and all participants in this study gave written,
informed consent. Synovial tissue from long duration disease was collected during
joint replacement surgery. Tissue from treatment-naive arthritis patients was col-
lected by ultrasound-guided synovial biopsy, collecting tissue from multiple regions
within knee, ankle, or metacarpophalangeal joints in which there was evidence of
gray-scale synovitis. Ultrasound guidance was used to introduce a single portal
through which tissue was sampled using custom-manufactured 2.0-mm cutting-
edged forceps or a 16 g core biopsy needle (metacarpophalangeal joint). Each
clinical sample originating from a patient gave rise to a cell line. Cells were grown
from six to eight individual biopsies in order to overcome synovial heterogeneity;
tissue samples were cut into small sections of approximately 1 mm3 using a sterile
scalpel. Sections were suspended in 6 ml of complete ﬁbroblast medium and
transferred into T25 ﬂasks. Lines were incubated at 37 °C in 5% CO2 and left
undisturbed for a week. Subsequently, medium was changed weekly. Synovial and
skin ﬁbroblasts were cultured with complete ﬁbroblast medium composed of
RPMI-1640, 10% non-heat inactivated fetal calf serum (FCS), 1% minimum
essential medium (MEM) nonessential amino acids, 100 mM sodium orthopyr-
uvate, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and used
between passages 4–8. Fibroblasts were fed once weekly and maintained in culture
until conﬂuence. At feeding, 66% of the culture medium (referred to as conditioned
medium) was discarded and replaced with fresh complete medium. Cells were
counted using a CountessTM II FL Automated Cell Counter (ThermoFisher
Scientiﬁc).
Laboratory animals. All animal studies were approved and performed under the
guidelines of the Ethical Committee for the Use of Animals, Barts and The London
School of Medicine and Home Ofﬁce regulations (Guidance on the Operation of
ASPA 1986) and complied with all relevant ethical regulations. C57BL/6NCrl were
purchased from Charles River. Mc1re/e/mice were obtained from The Jackson
Laboratory.Mc3r−/−mice were originally obtained from Dr. Howard Chen (Merck
Laboratories). For all in vivo studies, male, age-matched wild-type (WT) mice
were used.
Mouse primary SFs. Hindlegs were obtained from male C57BL/6NCrl, Mc1re/e,
and Mc3r−/− mice. Bones were cleaned of tissue before teasing bones apart to
expose synovial cavities. Tissues were enzymatically digested with 2.5 mg/ml col-
lagenase D (Roche) and 0.25 mg/ml DNase I (Sigma-Aldrich) for 45 min, and then
with 2.5 mg/ml collagenase/dispase (Roche) and 0.25 mg/ml DNase I for another
30 min. Cells were cultured in RPMI-1640 containing 10% FCS, 2 mM L-glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin. Media was changed every 3 days,
and cells sub-cultured at 80–90% conﬂuence. Cells were used at passage 5.
Human primary macrophages. Experiments using healthy volunteers (written
consent provided) were approved by the Queen Mary Ethics of Research Com-
mittee (QMREC2014.61). Blood was collected into 3.2% sodium citrate and diluted
1:1 in RPMI-1640 before separation through a double-density gradient using
Histopaque 1077/1119 (Sigma-Aldrich). Blood was layered on top of the double
histopaque layer (H1119 bottom, 1077 top) and centrifuged at 1340 r.p.m. for
30 min. The peripheral blood mononuclear cell (PBMC) layer was collected and
cells washed twice with phosphate-buffered saline (PBS). PBMCs were differ-
entiated into macrophages in complete media (RPMI-1640, 10% FCS, 2 mM glu-
tamine, 100 U/ml penicillin, 100 μg/ml streptomycin) in the presence of 50 ng/ml
M-CSF (Peprotech) during 7 days.
3D minisynovium organoids. Cells were centrifuged and pellet resuspended in
Matrigel® (Corning) at 1 × 106 cells/ml. Droplets (25 μl) were plated on 2% poly-
HEMA (Sigma-Aldrich)-coated plates and incubated for 1 h before addition of
culture media, the same as human SF cultures above. Spheroids were cultured for
3 weeks, ﬁxed in 4% PFA, and parafﬁn embedded.
Cell transfections. HEK293T (ATCC CRL-3216) cells were cultured in complete
media (DMEM, 10% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin) and transfected with MC1R, MC3R, MC4R, MC5R, or control
TrueORF cDNA clones (Origene) using Lipofectamine 2000 (Invitrogen) using 2 μl
Lipofectamine per 400 ng DNA in a ﬁnal volume of 100 μl of OptiMEM media,
added to 24-well plates containing 700 μl/well of complete media and used 24 h
after transfection. Mycoplasma contamination was tested using the LookOut®
Mycoplasma PCR Detection Kit (Sigma).
PathHunter β-Arrestin assay. A screening assay on the activation of 168 GPCR
was conducted using the gpcr MAX Panel service at Euroﬁns Proﬁling Services
(Fremont, CA). For agonist activity determination, cells expressing each of the
receptors and carrying the Enzyme Fragment Complementation technology were
treated with 10 μM of BMS for 90–180 min, and chemiluminescent signal mea-
sured 1 h after addition of detection reagent cocktail. Data are expressed as % of
control ligand (αMSH for MCRs and ghrelin for GHS receptor).
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K/BxN model of inﬂammatory arthritis. Arthritis was induced in male C57BL/
6NCrl mice (6 weeks old) with two i.p. injections of 100 or 150 μl of K/BxN serum
on days 0 and 2. Disease was monitored by assessing clinical score (score per paw:
0= no signs of inﬂammation, 1= subtle inﬂammation, localized, 2= easily iden-
tiﬁed inﬂammation but localized, 3= evident inﬂammation, not localized; max
score= 12). Signs of mild bone damage was detected in some mice, but this was
not consistent enough enable the monitoring of potential drug efﬁcacy in our
experimental settings. Drugs were administered i.p. on days 3–8 (BMS 18mg/kg)
and on days 4, 6, and 8 (dasatinib+ quercetin at 2.5 and 10 mg/kg, respectively).
This regimen was chosen to allow the induction of senescence with BMS and the
rapid elimination of senescent cells with the administration of senolytics. Doses
were chosen according to the route of administration and dosing schedule. To
account for potential non-senolytic off-target effects, a group of mice treated only
with senolytics was included. Tissues were ﬁxed with 4% neutral-buffered formalin
for 24 h, decalciﬁed on 10% EDTA for 4 weeks (for ankles and knees), and parafﬁn
embedded.
Compounds. The following compounds were used: αMSH (alpha-melanocyte
stimulating hormone), BMS-470539 (1-[1-(3-methyl-L-histidyl-O-methyl-D-tyr-
osyl)-4-phenyl-4-piperidinyl]-1-butanone dihydrochloride) and [D-Trp8]-γMSH
(Tocris); agouti signaling protein ASIP87–132 and agouti-related potein AGRP83–132
(Phoenix Pharmaceuticals); serum amyloid A (SAA; Peprotech); FR180204 (ERK1/
2 inhibitor; Merck); atorvastatin, 5β-cholanic acid, dasatinib, and quercetin (Sigma-
Aldrich); and DLL4 recombinant human protein (Thermo Scientiﬁc).
Enzyme-linked immunosorbent assay and enzyme immunoassays. The fol-
lowing kits were used following the manufacturer’s instructions: CCL-2 and IL-6
Ready-SET-Go ELISA (eBioscience); CXCL-5 DuoSet ELISA (R&D Systems);
ACTH EIA Fluorescent Kit (Phoenix Pharmaceuticals); cAMP Select EIA kit
(Cayman Chemical); ERK1/2 (pT202/Y204) SimpleStep ELISA Kit (Abcam); Bile
Acid Assay kit and Cholesterol Quantitation Kit (Sigma-Aldrich). The direct
adenylyl cyclase activator forskolin (3 μM, TOCRIS) was used as a positive control
in the cAMP assay.
Cell viability assay. Cells were incubated with Alamar Blue reagent (Invitrogen)
diluted 1:10 in PBS for 4 h at 37 °C/5% CO2. Fluorescence was measured at EX560/
EM590 on a NOVOstar reader (BMG Labtech).
Ca2+ mobilization assay. Cells were incubated with 2 μM Fura-2 AM (Thermo
Scientiﬁc) in HBSS without Ca2+ (Sigma-Aldrich) at 37 °C for 45 min in the dark
and washed with PBS. HBSS containing 0.185 g/l CaCl2 was then added prior to
stimulation with agonists at the indicated concentrations, or with 1 µM Ionomycin
(SIGMA) used as a positive control. Mobilization of intracellular Ca2+ was
quantiﬁed by recording the ratio of ﬂuorescence emission at 510 nm after
sequential excitation at 340/380 nm using the NOVOstar reader (BMG Labtech)
for 86 s. Data correspond to time 25 s after compound addition. Data presented
correspond to 25 s after drug addition.
iBIDI™ scratch assay. Cells were grown in two-well culture-Inserts (Ibidi) in
24-well plates in complete media (RPMI-1640, 10% non-heat inactivated FCS, 1%
MEM nonessential amino acids, 100 mM sodium orthopyruvate and 2 mM glu-
tamine, 100 U/ml penicillin, 100 μg/ml streptomycin) until conﬂuent. Inserts were
removed and cells washed prior stimulation with test compounds. Images were
acquired at times 0, 24, and 48 h. Gap size was quantiﬁed with ImageJ.
Cell migration assay. Cells were seeded in SF medium, as above, but without
serum on Transwell inserts (6.5 mm diameter, 8 μm pore size; Corning) coated
with Matrigel® Basement membrane matrix (Corning) for invasion assays, and
non-coated for migration assays. Ten percent FCS media was added to outer
compartment. Cells were incubated overnight, stained with 1% crystal violet
(Sigma-Aldrich), and counted.
Apoptosis assay. Cells were stained with FITC-AnxAV and propidium iodide (PI)
using the Apoptosis Detection Kit I (BD Pharmingen), by staining samples with
5 μl of Annexin A5 and 10 μl of PI for 15 min at room temperature and analyzed by
ﬂow cytometry (BD FACSCalibur™).
Western blotting analysis. Cells were lysed using RIPA buffer (Thermo Scientiﬁc)
containing Protease Inhibitors Cocktail at 1:100 dilution (Calbiochem). Samples
were subjected to standard SDS-PAGE, and transferred onto PVDF membranes
(Merck Millipore). Antibodies and dilutions used were: anti-phospho-ERK1/2
(1:1000; Cell Signaling), anti-ERK1/2 (1:1000; Cell Signaling), anti-α-Tubulin
(1:5000; Sigma-Aldrich), rabbit anti-p53 (1:2000; Abcam), HRP-conjugated anti-
rabbit and anti-mouse IgG (1:2000; Dako). Bands were quantiﬁed using ImageJ.
Immunoﬂuorescence analyses. Cells were ﬁxed with 4% PFA and permeabilized
with 0.3% Triton X-100. For mouse tissues, antigen retrieval was performed by
incubating slides in basic buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween 20,
pH 9.0), for 5 min at 95 °C. Samples were incubated overnight with primary
antibodies: anti-human/mouse p16INK4a (1:100; Abcam), anti-mouse p16INK4
(undiluted; CNIO, clone PABLO33B), anti-cadherin-11 (1:10; Cell Signaling), anti-
cleaved caspase-3 (1:100; Cell Signaling), anti-Notch3 (1:200; Abcam). Secondary
antibodies (1:100; Thermo Scientiﬁc) were incubated for 2 h: anti-mouse and anti-
rabbit IgG Alexa Fluor 594, anti-rabbit IgG Alexa Fluor 647, anti-rat IgG Alexa
Fluor 647. Slides were coverslip with ProLong Diamond Antifade Mountant with
DAPI (Thermo Scientiﬁc) and images acquired at ×20 magniﬁcation on the EVOS
FL Imaging System (Thermo Scientiﬁc). Exposure and sharpness were kept con-
stant for all images for comparison.
Cell and tissue staining. The following kits (Abcam) were used as per the
manufacturer’s instructions: Senescence Detection Kit (SA-βGal) and Fontana-
Masson (melanin). H&E staining was performed on de-parafﬁnized and rehydrated
sections using hematoxylin and eosin (Sigma-Aldrich) and mounted in Entellan
mounting medium. Cell inﬁltration was scored as: 0= not detected, 1=mild, 2=
moderate, 3= severe. Cartilage staining was performed with toluidine blue (1%,
10 min) (Sigma-Aldrich). Cartilage integrity (loss of sulfated proteoglycans stain-
ing) was scored as: 0= normal, 1=mild loss, 2=moderate loss, 3= total loss of
staining. Images were acquired at ×20 magniﬁcation on a Nanozoomer S210 Slide
Scanner (Hamamatsu). Exposure and sharpness were kept constant in all images
for comparison.
Melanin measurement. B16-F10 cells were cultured in 10% FCS αMEM. Cells
were treated for 4 days and stained with Fontana-Masson staining or centrifuged to
visualize melanin in cell pellets. Melanin content in supernatants was determined
by measuring absorbance at 405 nm.
Gene expression analyses. RNA was extracted using Direct-zol RNA MiniPrep
with in-column DNase I digestion (Zymo Research). cDNA was synthesized (1 μg
RNA) with SuperScript VILO MasterMix (Invitrogen). End-point PCR was per-
formed with ReddyMix PCR MasterMix (Thermo Scientiﬁc). Real time-PCR was
performed with Power SYBR Green PCR MasterMix (Applied Biosystems) on the
ABI Prism 7900HT Sequence Detection System. Expression was calculated as
2−ΔΔCt 53 using HPRT as a reference gene54. Quantitect primers (QIAGEN) used
are shown in Table S2, with an annealing temperature of 55 °C used for all primers.
RNA sequencing was conducted at Euroﬁns-GATC services (Konstanz, Germany)
using non-stranded random primed cDNA on an Illumina HiSeq Genome
Sequencer, sequence mode HSHOv4 SR50 (HiSeq rapid run, 50 bp single read).
Sequencing reads were aligned to the human genome build hg38/GRCh38 with the
HISAT2 aligner. Transcript quantiﬁcation was performed with htseq-count
(HTSeq package v0.6.1p1), using GENCODE v23 human gene annotation
(Ensembl release 81). The read count data were ﬁltered to keep genes that achieve
at least one read count per million (cpm) in at least four samples. Hence, to be
considered expressed, any given gene needs to reach a value of at least cmp= 1 in
at least the 25% of samples (i.e. 4 samples). Reads per kilobase per million mapped
reads (RPKM) values were calculated with the conditional quantile normalization
(cqn) counting for gene length and GC content in the R statistical environment via
Bioconductor. Genes with p > 0.05 were included yielding a working list of 1952
differentially expressed genes. This research utilized Apocrita HPC facility sup-
ported by QMUL research-IT. Data were deposited in GEO: access code GSE98658.
Functional analysis and databases. The functional analysis of the previously
identiﬁed differentially expressed genes (1952) was conducted with DAVID v6.8
and Panther Classiﬁcation System v12.0 by uploading the full set of genes. The gene
expression proﬁle induced by BMS was used to query the Connectivity Map v02
perturbation-driven gene expression dataset using default settings. PPI networks
were constructed using STRING v10.5 by uploading the full gene list and excluding
disconnected nodes from the resulting network. We also used information from the
following databases: CellAge Database vbeta, TiRe Database 1.0, and GPCR NaVa
Database.
MC1R gene sequencing. The entire coding region of MC1R was ampliﬁed using
the primers Forward: 5′-GAAGAACTGTGGGGACCTGG-3′ and Reverse: 5′-GG
GTCACACAGGAACCAGAC-3′. PCR products were puriﬁed with QIAquick Gel
Extraction Kit (QIAGEN) and subjected to Sanger sequencing at Euroﬁns-GATC
services (Konstanz, Germany) using an ABI 3730xl DNA Analyzer and basecaller
KB v1.4.1.8. Electropherograms were analyzed using *.ab1 ﬁles and variants
detected using SnapGene® Viewer v3.0.3 and the Homo sapiens MC1R reference
sequence NM_002386.3.
Statistical analysis. In each experiment included in this study, the value of n is
always deﬁned as number of biological replicates (e.g. participants, mice) and
not technical replicates. Statistical parameters including the exact n value for
each experiment, nature of data shown (mean ± SE or mean ± SD), and statistical
signiﬁcance are reported in the ﬁgure legends. Data are considered statistically
signiﬁcant when p < 0.05. One-tail Student t-test, one-way ANOVA, or two-way
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ANOVA were used as appropriate. In the ﬁgures, asterisks or hashes denote sta-
tistical signiﬁcance (*,#p < 0.05; **,##p < 0.01; ***p < 0.001). Statistical analysis was
performed in GraphPad PRISM v7.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the results presented herein are available from the corresponding
authors upon reasonable request. Raw data ﬁles for the RNA sequencing analysis have
been deposited in the NCBI Gene Expression Omnibus under accession number GEO:
GSE98658. The source data underlying graphs and un-cropped gels and blots in the main
ﬁgures and Supplementary Information are provided as a Source Data ﬁle.
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